

IPW/  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Eveleigh, et al.

Application No.: 10/764,425

Filed: 01/23/2004

Group No.: 1643


Examiner: Humphrey, David  
Harold

For: Expression Profiles for Colon Cancer and Methods of Use

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 17, 2006

  
Susan M. Pellegrino

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
ALEXANDRIA, VA 22202

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed **after** three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but **before** the mailing date of either

- (1) a final action under section 1.113 or
- (2) a notice of allowance under section 1.311 or
- (3) any other action closing prosecution

whichever occurs first.

08/22/2006 MBERHE 00000043 133372 10764425  
01 FC:1806 180.00 DA

**FEE**

2. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

**METHOD OF PAYMENT OF FEE**


3. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

Reg. No. 48,972

Telephone: (203) 812-6450

Date: August 17, 2006

  
\_\_\_\_\_  
Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

Form PTO-449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/764,425	Group Art Unit 1643	Filing Date 01/23/2004	Atty. Docket No. 5151
 1 of 1 <b>INFORMATION DISCLOSURE CITATION</b>		Applicant(s) Eveleigh, et al.			

U.S. PATENT DOCUMENTS													
*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
R1	NANNI, O., et al, Role of Biological Markers in the Clinical Outcome of Colon Cancer, Brit. J. of Cancer, 2002, Vol. 87, pgs. 868-875	
R2	UTHOFF S. M. S., et al., VEGF Isoforms and Mutations in Human Colorectal Cancer, Inter. J. of Cancer, 2002, Vol.101, pgs. 32-36	
R3	CASCINU, S., et al., Expression of Vascular Endothelial Growth Factor Can Predict Event-free Survival in Stage II Colon Cancer, Clinical Cancer Research, 2000, Vol. 6, pgs. 2803-2807	
R4	FOLGER, P.A., et al., A Mammalian Severin Replaces Gelsolin in Transformed Epithelial Cells, Cancer Research, 1999, Vol. 59, pgs. 5349-5355	
R5	FOX, S. H., et al., Angiogenesis in Normal Tissue Adjacent to Colon Cancer, Journal of Surgical Oncology, 1998, Vol. 69, pgs. 230-234	

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	